Luminex Stock Price, News & Analysis (NASDAQ:LMNX)

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex declared a quarterly dividend on Wednesday, July 31st. Stockholders of record on Thursday, September 26th will be paid a dividend of $0.09 per share on Thursday, October 17th. This represents a $0.36 dividend on an annualized basis and a dividend yield of 1.79%. The ex-dividend date of this dividend is Wednesday, September 25th. This is a positive change from Luminex's previous quarterly dividend of $0.06. View Luminex's Dividend History.

Luminex Co. (NASDAQ:LMNX) released its quarterly earnings data on Wednesday, July, 31st. The medical instruments supplier reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.09. The medical instruments supplier had revenue of $83.06 million for the quarter, compared to analysts' expectations of $81.61 million. Luminex had a negative net margin of 0.80% and a negative return on equity of 0.78%. The business's quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.15 EPS. View Luminex's Earnings History.

Luminex is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Luminex.

Luminex issued an update on its third quarter 2019 earnings guidance on Wednesday, July, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80-83 million, compared to the consensus revenue estimate of $83.01 million.

3 equities research analysts have issued 12 month target prices for Luminex's stock. Their predictions range from $21.00 to $33.00. On average, they expect Luminex's stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price. View Analyst Price Targets for Luminex.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.

News articles about LMNX stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Luminex earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Luminex.

Luminex saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 1,000,000 shares, a decline of 30.6% from the August 30th total of 1,440,000 shares. Based on an average daily trading volume, of 189,400 shares, the short-interest ratio is currently 5.3 days. Currently, 2.4% of the company's stock are sold short. View Luminex's Current Options Chain.

Some companies that are related to Luminex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), Mondi (MNDI), Alphabet (GOOG), Intel (INTC), Micron Technology (MU), Nektar Therapeutics (NKTR), Rocket Pharmaceuticals (RCKT), Verizon Communications (VZ), Cree (CREE) and Ligand Pharmaceuticals (LGND).

Luminex's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhumbline Advisers (0.32%), Bridge City Capital LLC (0.15%), State of Alaska Department of Revenue (0.07%) and Nisa Investment Advisors LLC (0.05%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Nachum Shamir and Todd C Bennett. View Institutional Ownership Trends for Luminex.

LMNX stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Bridge City Capital LLC, Rhumbline Advisers and Nisa Investment Advisors LLC. View Insider Buying and Selling for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $20.11.

Luminex has a market capitalization of $905.90 million and generates $315.82 million in revenue each year. The medical instruments supplier earns $18.51 million in net income (profit) each year or $0.48 on an earnings per share basis. Luminex employs 988 workers across the globe.View Additional Information About Luminex.

The official website for Luminex is http://www.luminexcorp.com/.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]